ArticleJournal of clinical microbiology2009
Identification of Cryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA sequencing.
Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 91 citations in OpenAlex.
- Plant amino acid analogues as antimicrobial agents.Amino acids · 2025Review
- Insights from Mass Spectrometry-Based Proteomics onJournal of fungi (Basel, Switzerland) · 2025Review
- Evolution of Laboratory Diagnostics for Cryptococcosis and Missing Links to Optimize Diagnosis and Outcomes in Resource-Constrained Settings.Open forum infectious diseases · 2024Review
- The arginine transporter Can1 negatively regulates biofilm formation in yeasts.Frontiers in microbiology · 2024Article
- A Comprehensive Review of Identification Methods for Pathogenic Yeasts: Challenges and Approaches.Advanced biomedical research · 2023Review
- What's New inJournal of fungi (Basel, Switzerland) · 2022Review
- Hidden in plain sight: urinary Cryptococcus neoformans missed by routine diagnostics in a patient with acute leukemia.Annals of clinical microbiology and antimicrobials · 2022Article
- Primary Cutaneous Cryptococcosis Caused byTropical medicine and infectious disease · 2022Article
- Development of a Real-Time PCR Assay to Identify and Distinguish betweenJournal of fungi (Basel, Switzerland) · 2022Article
- Prevalence of Cryptococcus gattii in Ugandan HIV-infected patients presenting with cryptococcal meningitis.PloS one · 2022Article
- Multilocus Sequence Typing of Clinical Isolates of Cryptococcus from India.Mycopathologia · 2021Article
- Article
- Emerging Cryptococcus gattii species complex infections in Guangxi, southern China.PLoS neglected tropical diseases · 2020Article
- Clinical and microbiological characteristics of Cryptococcus gattii isolated from 7 hospitals in China.BMC microbiology · 2020Article
- Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.PLoS neglected tropical diseases · 2019Article
- Article
- Cryptococcus gattii Complex Infections in HIV-Infected Patients, Southeastern United States.Emerging infectious diseases · 2018Article
- The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital.Revista do Instituto de Medicina Tropical de Sao Paulo · 2017Article
- First case of mixed infection withJMM case reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptococcus neoformans and Cryptococcus gattii are closely related pathogenic fungi. Cryptococcus neoformans is ecologically widespread and affects primarily immunocompromised patients, while C. gattii is traditionally found in tropical climates and has been reported to cause disease in immunocompetent patients. l-Canavanine glycine bromothymol blue (CGB) agar can be used to differentiate C. neoformans and C. gattii, but there are few reports of its performance in routine clinical practice. Growth of C. gattii on CGB agar produces a blue color, indicating the assimilation of glycine, while C. neoformans fails to cause a color change. Using reference and clinical strains, we evaluated the ability of CGB agar and D2 large ribosomal subunit DNA sequencing (D2 LSU) to differentiate C. neoformans and C. gattii. One hundred two yeast isolates were screened for urease activity, melanin production, and glycine assimilation on CGB agar as well as by D2 sequencing. Seventeen of 17 (100%) C. gattii isolates were CGB positive, and 54 of 54 C. neoformans isolates were CGB negative. Several yeast isolates other than the C. gattii isolates were CGB agar positive, indicating that CGB agar cannot be used alone for identification of C. gattii. D2 correctly identified and differentiated all C. gattii and C. neoformans isolates. This study demonstrates that the use of CGB agar, in conjunction with urea hydrolysis and Niger seed agar, or D2 LSU sequencing can be reliably used in the clinical laboratory to distinguish C. gattii from C. neoformans. We describe how CGB agar and D2 sequencing have been incorporated into the yeast identification algorithm in our laboratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.